TRINTELLIX® (vortioxetine) is indicated for the treatment of Major Depressive Disorder (MDD) in adults.

Patient portrayal.
Individual results may vary.

Resources

Important resources for your patients, your practice, and you

Resources for your patients

Help your patients connect to these important resources for savings information, support, self-assessment, and more.

Patient brochure

Symptoms of major depressive
disorder, safety information
and the benefits of TRINTELLIX
are explained here.

Download PDF

tAccess support program and savings card brochure

Connect your patients to
information about savings, support
and more with the tAccess brochure.

Download PDF

Patient health questionnaire (PHQ-9) screener

Patients can use this
self-assessment tool to help HCPs
understand the nature and severity
of their symptoms.

Download PDF

Additional patient resources

Trintellix patient resources

The TRINTELLIX patient website has
additional tools and resources for
your patients, explaining their
options, and keeping them informed.

View patient site

Help at Hand patient
assistance program

Takeda may be able to help patients
without prescription insurance, or
those having difficulty affording
their medications.

Learn more

Resources for your practice

Stay prepared and up-to-date with these essential resources.

Patient health questionnaire (PHQ-9) scoring card

Used in tandem with the PHQ-9
screener, this card helps HCPs assess
and understand patient symptoms.

Download PDF

TRINTELLIX dosing card

Dosing Card

Dosage guidance, food restrictions,
and more are all explained on this card.

Download PDF

Resources for telehealth

These tools may help your patients and practice get ready for effective telehealth visits.

Patient telehealth guide

This brochure may help patients
prepare for their next telehealth
appointment.

Download PDF

American Psychiatric
Association telepsychiatry
toolkit

American Psychiatric Association Telepsychiatry Toolkit

This toolkit is an ever-growing
resource helping HCPs learn more
about telepsychiatry.

Visit site

American Medical Association
quick guide to telemedicine
in practice

American Medical Association Telehealth quick guide

An informative guide to real-time
communication tools, remote patient
monitoring, and more.

Visit site

What to explore next?

Leaving TRINTELLIXHCP.COM

By clicking “Continue,” you will be leaving a Takeda and Lundbeck controlled website for a third-party website.

Please note that neither Takeda nor Lundbeck is responsible or liable for any third-party website, and the website may not be appropriate for all audiences.

CONTINUE
CANCEL

  1. Trintellix (vortioxetine) prescribing information. Takeda Pharmaceuticals.
  2. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of LuAA21004 in patients with Major Depressive Disorder. Int J Neuropsychopharmacol. 2012;15(5):589-600.
  3. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with Major Depressive Disorder. J Clin Psychiatry. 2012;73(7):953-959.
  4. Boulenger J-P, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with Major Depressive Disorder. Int Clin Psychopharmacol. 2014;29(3):138-149.
  5. Mahableshwarkar AR, Jacobsen P, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine‑referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 2015;232(12):2061-2070.
  6. Jacobsen P, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with Major Depressive Disorder. J Clin Psychiatry. 2015;76(5):575-582.
  7. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with Major Depressive Disorder. Int Clin Psychopharmacol. 2012;27(4):215-223.
  8. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557-1567.
  9. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in Major Depressive Disorder. Neuropsychopharmacology. 2015;40(8):2025-2037.
  10. Data on file. Takeda Pharmaceuticals.
  11. Data on file. Lundbeck.
  12. Boulenger J-P, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with Major Depressive Disorder. J Psychopharmacol. 2012;26(11):1408-1416.
  13. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well‑treated Major Depressive Disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015;12(10):2036-2048.
  14. Kambeitz JP, Howes OD. The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord. 2015;186:358-366.
  15. American Psychiatric Association. Depressive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th edition (DSM-5®). Arlington, VA: American Psychiatric Association; 2013:155-188.
  16. ICD-10-CM Tabular list of diseases and injuries. Centers for Medicare & Medicaid Services. Published 2022. https://www.cms.gov/files/zip/2022-code-tables-tabular-and-index-updated-02012022.zip. Accessed August 19, 2022.